ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,334.20
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,351.59
1.20%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NewAmsterdam Pharma Company NV (NAMS) Share Price

NAMS NewAmsterdam Pharma Company NV

18.82
-0.28 (-1.47%)
25 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 NewAmsterdam Pharma Company NV NASDAQ:NAMS NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.28 -1.47 18.82 17.63 20.95 20.3263 18.51 19.11 131,706 00:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics 14.09M -176.94M -1.9821 -9.47 1.68B
 Type  Size  Price  Time  Units 
 9 90 19.76 20:02:38 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NAMS News
21/05/202413:00GLOBENewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
09/05/202413:00GLOBENewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
03/05/202421:01GLOBENewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05/202413:00GLOBENewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
09/04/202413:00GLOBENewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
01/04/202413:00GLOBENewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
25/03/202412:00GLOBENewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Period
Draw mode
Data Downloads for NAMS

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest NewAmsterdam Pharma Company NV Articles